FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to internal diseases, gastroenterology, hepatology, endocrinology, dietology, and can be used for treating non-alcoholic fatty liver disease (NAFLD). In the dietary program for men one consumes soup 150 g + 150 g of protein + 150 g of vegetables, for dinner - 200 g of cereals and 200 g of vegetables, or 400 g of vegetables. In the nutrition program for women, for lunch one consumes 150 g of protein + 100 g of vegetables, and for dinner one consumes 150 g of groats + 250 g of vegetables, or 300 g of vegetables. Breakfast is consumed in the form of curd, eggs with vegetables, oatmeal, cottage-cheese pancakes with sour cream, bread with cheese and vegetables, yoghurt; a portion for men is 250-350 g, for women - 200-250 g. Snacks are consumed in the form of fruits, berries and fresh juices; the portion size for men is 200-250 g, for women - 150-200 g. Drinking regimen includes 1.75-3.5 l of liquid a day. Men without physical activity need to consume 3 g of salt a day, men with physical activity - 3.5 g of salt a day, women without physical activity - 2.5 g of salt a day, women with physical activity - 3.0 g of salt a day and sugar is consumed from 10 to 30 grams a day with warm liquid after meals. Entero- and phytosorbents are used. Physical activity consists of daily walking of 3000 steps a day and more, walking in fresh air for 20 minutes to 1 hour. Lymphatic drainage exercises are performed for 12-45 minutes and breathing exercises with inhalation through the nose and exhalation through the mouth with duration of inhalation and exhalation from 5 to 8 seconds.
EFFECT: method provides reducing the degree of obesity, hepatic steatosis and other metabolic disorders by reducing fat drops in hepatocytes, increasing tissue sensitivity to insulin, reducing the level of hepatic enzymes ALT, AST, gamma-GT, ALP, total cholesterol, triglycerides, low-density lipoproteins, insulin, glucose, high-density lipoproteins, improves liver ultrasound, due to a combination of techniques of the claimed invention.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
METHOD FOR THE DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN MEN OF THE EUROPEAN POPULATION DURING SCREENING EXAMINATIONS | 2021 |
|
RU2760092C1 |
METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
METHOD OF DIAGNOSING METABOLIC SYNDROME | 2010 |
|
RU2444298C1 |
METHOD FOR TREATMENT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE USING SPECIALIZED FOOD PRODUCT | 2021 |
|
RU2761164C1 |
METHOD OF PERSONIFIED PREDICTION OF CLINICAL EFFECTIVENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME | 2020 |
|
RU2737503C1 |
METHOD OF DETERMINING THE RISK OF SEVERE LIVER STEATOSIS | 2023 |
|
RU2806496C1 |
DIAGNOSTIC TECHNIQUE FOR DRUG-INDUCED LIVER INJURY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2695021C1 |
METHOD OF NON-INVASIVE DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN MEN | 2023 |
|
RU2803074C1 |
Authors
Dates
2025-04-11—Published
2023-12-25—Filed